Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease

计划入组 60 人 · 首次发布于 2024 年 7 月 17 日

Sarcopenia Among Patients With Metabolic Dysfunction-associated Steatotic Liver Disease

计划入组 120 人 · 首次发布于 2026 年 5 月 20 日

Prevalence of Obesity in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

计划入组 200 人 · 首次发布于 2026 年 3 月 5 日

Metabolic dysfunction-associated steatohepatitis(Cellarity)

liver disease program

siRNA therapy (sc, metabolic dysfunction-associated steatohepatitis)

METABOLIC THERAPY, INC.

United States

Metabolic Technologies, Inc.

United States

Associated Capital

United States

Rising Liver Cancer Cases in the US Linked to Alcohol-Associated Liver Disease and MASLD

Pfizer's Novel MASH Treatment Combination Clesacostat/Ervogastat Projects $16M Revenue by 2036

Sagimet's Denifanstat Receives FDA Breakthrough Therapy Designation for MASH